151 related articles for article (PubMed ID: 30316683)
1. ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer.
Bakkenist CJ; Lee JJ; Schmitz JC
Clin Colorectal Cancer; 2018 Dec; 17(4):255-257. PubMed ID: 30316683
[No Abstract] [Full Text] [Related]
2. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous nuclear ribonucleoprotein L facilitates recruitment of 53BP1 and BRCA1 at the DNA break sites induced by oxaliplatin in colorectal cancer.
Hu W; Lei L; Xie X; Huang L; Cui Q; Dang T; Liu GL; Li Y; Sun X; Zhou Z
Cell Death Dis; 2019 Jul; 10(8):550. PubMed ID: 31320608
[TBL] [Abstract][Full Text] [Related]
4. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.
Sundar R; Miranda S; Rodrigues DN; Chénard-Poirier M; Dolling D; Clarke M; Figueiredo I; Bertan C; Yuan W; Ferreira A; Chistova R; Boysen G; Perez DR; Tunariu N; Mateo J; Wotherspoon A; Chau I; Cunningham D; Valeri N; Carreira S; de Bono J
Clin Colorectal Cancer; 2018 Dec; 17(4):280-284. PubMed ID: 30042009
[TBL] [Abstract][Full Text] [Related]
5. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.
Zhou Y; Wan G; Spizzo R; Ivan C; Mathur R; Hu X; Ye X; Lu J; Fan F; Xia L; Calin GA; Ellis LM; Lu X
Mol Oncol; 2014 Feb; 8(1):83-92. PubMed ID: 24145123
[TBL] [Abstract][Full Text] [Related]
6. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
[TBL] [Abstract][Full Text] [Related]
7. Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines.
Noordhuis P; Laan AC; van de Born K; Honeywell RJ; Peters GJ
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31344863
[TBL] [Abstract][Full Text] [Related]
8. Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.
Ballout F; Lu H; Bhat N; Chen L; Peng D; Chen Z; Chen S; Sun X; Giordano S; Corso S; Zaika A; McDonald O; Livingstone AS; El-Rifai W
Clin Cancer Res; 2024 May; 30(10):2193-2205. PubMed ID: 38592373
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide single-nucleotide resolution of oxaliplatin-DNA adduct repair in drug-sensitive and -resistant colorectal cancer cell lines.
Vaughn CM; Selby CP; Yang Y; Hsu DS; Sancar A
J Biol Chem; 2020 May; 295(22):7584-7594. PubMed ID: 32299912
[TBL] [Abstract][Full Text] [Related]
10. Escin-induced DNA damage promotes escin-induced apoptosis in human colorectal cancer cells via p62 regulation of the ATM/γH2AX pathway.
Wang Z; Chen Q; Li B; Xie JM; Yang XD; Zhao K; Wu Y; Ye ZY; Chen ZR; Qin ZH; Xing CG
Acta Pharmacol Sin; 2018 Oct; 39(10):1645-1660. PubMed ID: 29849127
[TBL] [Abstract][Full Text] [Related]
11. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
13. Recently emerging signaling landscape of ataxia-telangiectasia mutated (ATM) kinase.
Farooqi AA; Attar R; Arslan BA; Romero MA; ul Haq MF; Qadir MI
Asian Pac J Cancer Prev; 2014; 15(16):6485-8. PubMed ID: 25169474
[TBL] [Abstract][Full Text] [Related]
14. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Bahrami A; Amerizadeh F; Hassanian SM; ShahidSales S; Khazaei M; Maftouh M; Ghayour-Mobarhan M; Ferns GA; Avan A
J Cell Physiol; 2018 Mar; 233(3):2193-2201. PubMed ID: 28422287
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.
McCabe N; Hanna C; Walker SM; Gonda D; Li J; Wikstrom K; Savage KI; Butterworth KT; Chen C; Harkin DP; Prise KM; Kennedy RD
Cancer Res; 2015 Jun; 75(11):2159-65. PubMed ID: 25870146
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of nucleolar transcription by oxaliplatin involves ATM/ATR kinase signaling.
Nechay M; Wang D; Kleiner RE
Cell Chem Biol; 2023 Aug; 30(8):906-919.e4. PubMed ID: 37433295
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells.
Zhang P; Chen Z; Ning K; Jin J; Han X
Biochem Biophys Res Commun; 2017 Aug; 490(3):1132-1138. PubMed ID: 28676400
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy.
Vecchio D; Frosina G
Curr Drug Targets; 2016; 17(2):139-53. PubMed ID: 25382204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
